- Land: Deutschland
Nachricht vom 29.05.2019 | 17:35
Precisis AG: A promising treatment option from the perspective of doctors and patients - Innovative neurostimulation method persuasive among the first focal epilepsy patients (news with additional features)
Basel/Heidelberg, May 24, 2019 - Some 30% of all epilepsy patients cannot be treated satisfactorily despite a wide range of medication options. The condition restricts the people affected severely. To increase the chance of better epilepsy control and thus better quality of life, the new EASEE(R) stimulation method is currently being tested in the so-called clinical phase following successful preclinical trials. The first implantations have already been carried out successfully. In the run-up to this year's Annual Meeting of the German and Austrian Society for Epileptology and the Swiss Epilepsy League, renowned experts discussed the restrictions epilepsy patients have in everyday life, the limits of current treatment options and the opportunities EASEE(R) can offer for patients with drug-resistant focal epilepsy.*
During the event, Professor Christoph Helmstaedter, head of the Neuropsychology Department at the Clinic and Polyclinic for Epileptology at Bonn University Hospital, explained that stimulation methods can also have a positive effect on mood and cognition. "Several studies were able to prove the close and, in some instances, reciprocal relationship between epilepsy and cognition and behavior," says the expert. Patients could benefit in three ways: first, by controlling the disruptive epilepsy; second, by reducing the medication burden; third, by the stimulation itself. "It therefore remains exciting to see what will still be possible with EASEE(R) as a treatment option in terms of improving the brain function and quality of life of patients with functional cerebral diseases," concluded Professor Christoph Helmstaedter.
* Source: Make living with epilepsy easier - EASEE(R) Innovation Forum of Precisis AG on May 7, 2019 in Basel, Switzerland.
** First and last name of patient changed, pseudonym.
About Precisis AG
Precisis AG stands for outstanding successes in the field of therapies for the brain that are controlled by apparatuses We are committed to progress and develop individualized and precise treatment methods in the field of neurostimulation to make life easier for seriously ill patients. An ethical and responsible approach to the complex technical possibilities is deeply rooted in our employees' identity. In cooperation with some strong partners, we are therefore able to provide reliable solutions for people with functional cerebral diseases.
EASEE(R) stands for 'Epicranial Application of Stimulation Electrodes for Epilepsy'.
Further information about the activities, progresses, and milestones in the history of Precisis AG can be found on our website: www.precisis.de.
End of Media Release
Subtitle: EASEE-Elektrode (c)Precisis AG
Issuer: Precisis AG
Key word(s): Research/Technology
Precisis AG: second round of funding secured a ...
PRECISIS Aktiengesellschaft: Bekanntmachung de ...
Precisis AG: Precisis entwickelt neuartiges Sy ...
Precisis AG prepares Praezis Plus(R) NG launch
Precisis AG contributes to new software for ad ...
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
04. Dezember 07:00 Einstiegschance voraus! Dieser Hot-Stock plant mit dem "Netflix für ...
04. Dezember 07:15 Bitcoin & Co: Brutaler Abverkauf – ist die Party jetzt vorbei?
04. Dezember 08:00 Top-Tipp Derivate: Luxus in der Warteschleife
04. Dezember 08:05 China-Aktien, Bitcoin & Co: Risiko-Assets werden verkauft
04. Dezember 08:45 Deutsche Telekom: 50 Prozent Potenzial - wann gelingt die Trendwende?
News im Fokus
Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an
03. Dezember 2021, 07:03
FY 2020/2021 Financial Results
16. Dezember 2021
Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen
02. Dezember 2021